|
Pembrolizumab (pembro) vs paclitaxel (PTX) for previously treated advanced gastric or gastroesophageal junction (G/GEJ) cancer: Phase 3 KEYNOTE-061 trial. |
|
|
Consulting or Advisory Role - Agios; Bayer; Dicerna; Entrinsic Health; Five Prime Therapeutics; Genentech/Roche; Gilead Sciences; KEW; Lilly; Merck; Merrimack; Sanofi; Taiho Pharmaceutical |
|
|
|
Consulting or Advisory Role - Astellas Oncology |
Speakers' Bureau - Janssen |
Travel, Accommodations, Expenses - Pfizer; Roche |
|
|
Consulting or Advisory Role - BeiGene; Samyang |
Research Funding - AstraZeneca/MedImmune (Inst); Bayer (Inst); BeiGene (Inst); Boehringer Ingelheim (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Chong Kun Dang Pharmaceutical (Inst); Curis (Inst); Five Prime Therapeutics (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Green Cross (Inst); Lilly (Inst); Macrogenics (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst) |
|
|
No Relationships to Disclose |
|
|
Honoraria - Bristol-Myers Squibb; Merck; Novartis; Roche |
Consulting or Advisory Role - Bristol-Myers Squibb; Merck; Novartis; Roche |
|
|
Honoraria - Bristol-Myers Squibb; DAEHWA Pharmaceutical; Lilly; Ono Pharmaceutical |
Consulting or Advisory Role - Bristol-Myers Squibb; DAEHWA Pharmaceutical; Lilly; Ono Pharmaceutical |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; MSD |
Speakers' Bureau - Bayer; Bristol-Myers Squibb; Lilly; MSD |
Research Funding - Astellas Pharma; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; GlaxoSmithKline; Medivation; Merck Sharp & Dohme; Roche |
Travel, Accommodations, Expenses - Boehringer Ingelheim; Bristol-Myers Squibb |
Other Relationship - Boehringer Ingelheim |
|
|
Consulting or Advisory Role - Bristol-Myers Squibb; Celltrion; Lilly; Merck Serono; MSD; Quintiles; Taiho Pharmaceutical |
Speakers' Bureau - Foundation medicine; Lilly; Merck Serono |
Research Funding - Bristol-Myers Squibb; GlaxoSmithKline; Lilly; Merck Serono; MSD; Taiho Pharmaceutical |
|
|
Honoraria - Chugai Pharma; Lilly; Merck Serono; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Honsha |
Research Funding - Daiichi Sankyo; Gilead Sciences; Kyowa Hakko Kirin; MSD; Ono Pharmaceutical; Shionogi |
|
|
Consulting or Advisory Role - Bristol-Myers Squibb; Lilly; MSD; Pfizer; Roche; Sanofi |
Travel, Accommodations, Expenses - Lilly; MSD |
|
|
Consulting or Advisory Role - Ipsen; Novartis |
Speakers' Bureau - Bristol-Myers Squibb |
Travel, Accommodations, Expenses - Ipsen; Novartis |
|
|
Honoraria - Astellas Pharma; Bayer; Bristol-Myers Squibb; Clovis Oncology; Janssen; Merck Sharp & Dohme; Novartis; Pfizer; Sanofi |
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Janssen (Inst); Sanofi (Inst) |
Travel, Accommodations, Expenses - Janssen-Cilag; Pfizer; Roche |
|
|
No Relationships to Disclose |
|
|
|
|
|
No Relationships to Disclose |
|
|
|
|
|
|
Research Funding - Bristol-Myers Squibb |
|
|
Honoraria - Abbvie; Novartis; Ono Pharmaceutical; Yakult Pharmaceutical |
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb/Medarex; Lilly; Pfizer; Takeda |
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Lilly (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst) |